Table 1.

Summary of Key Characteristics of Randomized Controlled Trials of Mammography Screening.

Study (year began)Age (yr)Screening ProvidedRounds (of Mammography) (No)Screening Interval (mo)ViewsCompliance Rounds (%)Crossovers (Controls Who Had Mammography) (%)Follow-up (yr)Breast Cancer Mortality* RRAbsolute Risk Reduction in Breast Cancer Mortality (per 1,000)Number Needed to Screen 10 yr
HIP11 ,12 (1963)40–64M + CBE vs UC41221 = 67Data not available130.831.4193916
N = 61,0002–4 = 54–46(0.7–1.0)
Malmo13 (1976)45–70M vs UC918–241–21 = 742511–130.811.01271,185
N = 68,0002–5 = 70(0.62–1.07)
Two-Country14 (1977)40–74M vs UC324–3311 = 8913100.681.8095553
N = 126,0002–3 = 83–84(0.5–0.93)
Stockholm15 ,16 (1981)40–64M vs UC224–2811 = 81Controls offered screening yr 57.40.710.53691,378
N = 60,0002 = 81(0.4–1.2)
Gothenburg17 (1982)39–59M vs UC5181–21 = 852080.860.32862,435
N = 40,0002–5 = 77–78(0.54–1.37)
Edinburgh18 ,19 (1979)45–64M + CBE vs UC4241–21 = 66Data not available140.710.9451,482
N = 45,0007 = 44(0.53–0.95)
Canada 120 ,21 (1980)40–49M + CBE vs single CBE4–51221 = 10025130.98No reductionNot applicable
N = 50,0002–4 = 85–89(0.73–1.31)
Canada 221 ,22 (1980)50–59M + CBE vs CBE4–51221 = 1001610.51.14No reductionNot applicable
N = 40,0002–5 = 87–90(0.83–1.56)
  • RR = relative risk, N = number of participants, M = screening mammography, CBE = clinical breast examination, UC = usual care.

  • * Length of follow-up reported for various times up to 20 years. Data estimates were closest to 10-year point.

  • Number needed to screen corrected for 10 years of screening.